Centessa Pharmaceuticals plc
- Jurisdiction
United Kingdom - LEI
213800GIDAARDSKOI827 - ISIN
US1523091007 (CNTA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Read full profile
Fundamentals
- Net revenue
€12.79M - Gross margin
97.4% - EBIT
-€176.06M - EBIT margin
-1,376.1% - Net income
-€196.50M - Net margin
-1,535.8%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
| N/A |
| |
| N/A |
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| HUSSAIN IQBAL J | General Counsel |
|
|
|
|
| Accardi Mario Alberto | President, Orexin Program |
|
|
|
|
| Weinhoff Gregory M | Chief Business Officer |
|
|
|
|
| SAHA SAURABH | Chief Executive Officer |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |